A5084589856- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Tryptophan and brain disorders
- Molecular Biology Techniques and Applications
- Bipolar Disorder and Treatment
- Renal cell carcinoma treatment
- Cancer Cells and Metastasis
- Stress Responses and Cortisol
- Diet and metabolism studies
- Antioxidant Activity and Oxidative Stress
- Dementia and Cognitive Impairment Research
- Influenza Virus Research Studies
- Lung Cancer Diagnosis and Treatment
- Alzheimer's disease research and treatments
- Genetic factors in colorectal cancer
- Proteins in Food Systems
Kurchatov Institute
2023
Cedars-Sinai Medical Center
2018
City of Hope
2018
University of California, Irvine
2018
University of California, Los Angeles
2018
Liquid biopsies represent an attractive alternative to tissue biopsies, particularly rebiopsies, in determining patient eligibility for targeted therapies. Clinical utility of urine genotyping, however, has not been explored extensively. We evaluated epidermal growth factor receptor (EGFR) T790M detection matched urine, plasma, and the clinical outcomes patients with advanced non-small-cell lung cancer treated rociletinib.Tissue (n = 540), plasma 482), 213) were collected from evaluable...
8081 Background: Acquisition of the EGFR T790M resistance mutation is a hallmark disease progression in patients with metastatic mutant lung adenocarcinoma treated anti-EGFR inhibitors. Biopsies are challenging relapsed and non-invasive approach to detecting desired. We sought monitor urinary circulating tumor (ct) DNA for early acquisition understand ctDNA kinetics on treatment. Methods: In biomarker study 100 EGFR-mutated (39 enrolled), urine samples were obtained at different time points...
Alzheimer's disease is the most common neurodegenerative in old age. In some cases, it preceded by mild cognitive impairment (MCI). One of important components pathogenesis neurodegeneration chronic neuroinflammation (inflammatory activation microglia and astrocytes brain). Systemic inflammatory response immune dysregulation may contribute to neuroinflammation. The purpose this study was investigate level chemokines other mediators patients with MCI who underwent medical rehabilitation, its...
Abstract Introduction: An estimated 90% of pancreatic cancers harbor somatic KRAS G12/G13 mutations. The presence circulating tumor DNA (ctDNA) mutations at diagnosis has prognostic implications, however, recent studies on small numbers patients demonstrate widely variable ctDNA sensitivity (27 – 71%). Accurate identification both the and quantification number mutant copies would be an improved therapeutic response biomarker over CA19-9 which is known to uninformative in 5-10% with cancer. A...
11048 Background: Tumor heterogeneity and clonal selection contribute to resistance molecular targeted therapies. Dynamic tracking of urine cfDNA mutations can offer a noninvasive tool for monitoring therapeutic efficacy. Methods: was isolated from single or sequential samples patients with advanced cancers archival tumor tissue BRAF V600E CLIA-certified laboratory. Assays quantitative detection KRAS G12/13 in were developed using digital droplet (dd) PCR next generation sequencing....
Schizophrenia is a severely disabling and clinically heterogeneous disease that manifests with disorders of thinking, motivation emotions. Negative symptoms schizophrenia include decreased expression emotions, poverty speech, withdrawal from social contacts, anhedonia. They poorly respond to therapy, their severity has the most significant impact on functioning quality life patients. Changes in systemic immunity pronounced negative are studied. We have previously shown relationship elevated...
Abstract Introduction: Non-invasive urinary ctDNA-based liquid biopsy approach can be used to detect and track cancer driver mutations for rapid diagnosis disease monitoring. Using highly sensitivity ctDNA mutation detection platform, we examined the of KRAS G12/13 in urine obtained from advanced patients, assessed sample requirements, compared results with matched tumor tissue patients cancers. Methods: 41 solid on archival CLIA laboratory testing were prospectively enrolled informed...
e19092 Background: Radiographic imaging in lung adenocarcinoma patients is not always reliable and a non-tissue based approach for monitoring treatment responses or minimal residual disease desired. 15–25% of with have tumor associated KRAS mutations, these may be detected circulating (ct) DNA. The aim this study was to correlate the dynamics mutational load ctDNA clinical receiving surgical treatment, radiation, chemotherapy. Methods: In blinded biomarker 30 patients, urine samples were...
Abstract Background: The median overall survival (OS) time of patients with non-resectable pancreatic cancer varies widely. Diagnostic tools are presently lacking to predict patient outcome at diagnosis. vast majority tumors harbor KRAS mutations. In this study, we evaluated whether quantitative baseline and longitudinal monitoring mutations in plasma circulating tumor DNA (ctDNA) may be used stratify for predicting outcome. Methods: Danish BIOPAC study prospectively collected from...
Abstract Background: Colorectal cancer (CRC) is the third most commonly diagnosed and leading cause of deaths. Over half patients with CRC will develop liver metastases. Surgical resection, in combination systemic therapies, greatly improves long-term outcomes, around 40% resected limited disease are alive 5 years after diagnosis. While tumor staging radicality surgery used for prognostic assessment, better non-invasive markers needed monitoring chemo-responsiveness, following minimal...
Abstract Background: The acquisition of suitable tumor tissue is a challenge for significant fraction late-stage NSCLC patients who require EGFR testing to inform choice therapy. An alternative these could be the assessment mutations in circulating DNA (ctDNA). In this study, we examined detection T790M mutation ctDNA from urine, assessed urine sample requirements, and compared results with contemporaneously matched plasma TIGER-X (NCT01526928), Phase 1/2 clinical study rociletinib...
3594 Background: Over half of patients with CRC will develop liver metastases. Surgical resection greatly improves outcomes in these patients. Non-invasive markers are needed to better monitor treatment responses and guide complex decisions. This study evaluated the utility quantifying KRAS mutation burden urine plasma ctDNA for monitoring MRD surgical Methods: A blinded retrospective analysis was conducted 20 Stage I-IV positive primary tumor, 16 whom had undergone curative or palliative...